Ziprasidone is an atypical antipsychotic used to treat schizophrenia and bipolar disorder. It works by blocking dopamine d2 receptors in the brain, which helps reduce psychotic symptoms such as hallucinations and delusions. In addition, it acts as a serotonin 5-ht2a receptor antagonist, enhancing its antipsychotic effects. By modulating these neurotransmitter pathways, Ziprasidone stabilizes mood and improves cognitive function in patients with mood disorders. The medication's active ingredient influences physiological processes such as neurotransmission and receptor signaling to achieve therapeutic outcomes. Its pharmacological action primarily involves dopamine antagonism combined with serotonergic blockade which leads to symptom relief. The drug also has partial agonist activity at norepinephrine transporter sites which further contributes to its therapeutic profile. Overall Ziprasidone provides symptom control through targeted receptor interaction and neural circuitry modulation

Ziprasidone is an atypical antipsychotic medication used primarily to treat schizophrenia and acute manic episodes. It functions by blocking dopamine d2 receptors and serotonin 5-ht2a receptors in the brain. By antagonizing these receptors the drug reduces excessive dopaminergic signaling that contributes to psychotic symptoms. The same receptor blockade also modulates glutamatergic activity which enhances its antipsychotic effect. Ziprasidone has minimal antagonism at histamine and cholinergic receptors which limits sedative and anticholinergic side effects. Its pharmacological profile includes partial agonism at some serotonin receptors which helps stabilize mood regulation. The combined blockade leads to improved control of hallucinations delusions and mood elevation without significant weight gain. Clinically the medication is valued for its rapid onset in acute mania and its efficacy in treatment resistant psychotic states.

Ziprasidone may cause drowsiness or fatigue in some patients. Some individuals experience dizziness or lightheadedness when standing up quickly. Nausea or stomach discomfort can occur, especially during the first few weeks of treatment. Weight gain and increased appetite have been reported as common metabolic effects. Restlessness or an inability to sit still may be observed in a minority of users. Constipation or changes in bowel habits are also noted among patients taking the medication. Less frequently, mild headache or blurred vision may appear without requiring immediate medical attention.

Ziprasidone is an atypical antipsychotic medication used primarily for schizophrenia and bipolar disorder. It can cause drowsiness or sedation in some patients. Weight gain and increased appetite are reported side effects. Patients may experience dizziness or lightheadedness when rising quickly. Electrolyte changes such as low magnesium or potassium levels have been observed. Some individuals develop qt prolongation which can affect heart rhythm. Gastrointestinal symptoms like nausea or constipation may occur. These effects are generally mild but can vary among individuals.